MA30728B1 - Derives hydroxy-tetrahydro-naphtalenyluree - Google Patents

Derives hydroxy-tetrahydro-naphtalenyluree

Info

Publication number
MA30728B1
MA30728B1 MA27935A MA27935A MA30728B1 MA 30728 B1 MA30728 B1 MA 30728B1 MA 27935 A MA27935 A MA 27935A MA 27935 A MA27935 A MA 27935A MA 30728 B1 MA30728 B1 MA 30728B1
Authority
MA
Morocco
Prior art keywords
tetrahydro
pain
derivatives
naphthalene derivatives
naphthalenyluree
Prior art date
Application number
MA27935A
Other languages
English (en)
Inventor
Takeshi Yura
Muneto Mogi
Klaus Urbahns
Hiroshi Fujishima
Tsutomu Masuda
Toshiya Moriwaki
Nagahiro Yoshida
Toshio Kokubo
Masahiro Shiroo
Masaomi Tajimi
Yasuhiro Tsukimi
Noriyuki Yamamoto
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of MA30728B1 publication Critical patent/MA30728B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/40—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES DÉRIVÉS TÉTRAHYDRO-NAPHTALÈNE ET CERTAINS DE LEURS SELS, CONVENANT COMME PRINCIPE ACTIF DE PRÉPARATIONS PHARMACEUTIQUES. LES DÉRIVÉS TÉTRAHYDRO-NAPHTALÈNE DE LA PRÉSENTE INVENTION, QUI PRÉSENTENT UNE EXCELLENTE ACTIVITÉ COMME ANTAGONISTE DES VR1, CONVIENNENT POUR LA PROPHYLAXIE ET LE TRAITEMENT D'AFFECTIONS ASSOCIÉES À L'ACTIVITÉ DES VR1. LES AFFECTIONS CONCERNÉES SONT ESSENTIELLEMENT L'INCONTINENCE URINAIRE PAR IMPÉRIOSITÉ, LA VESSIE HYPERACTIVE, LA DOULEUR CHRONIQUE, LA DOULEUR NEUROPATHIQUE, LA DOULEUR POSTOPÉRATOIRE, LA DOULEUR DE LA POLYARTHRITE RHUMATOÏDE, LA NÉVRALGIE, LES NEUROPATHIES, L'ALGIE, LE TRAUMATISME NERVEUX, L'ISCHÉMIE, LA DÉGÉNÉRESCENCE NERVEUSE, L'ICTUS CÉRÉBRAL, L'INCONTINENCE, ET LES TROUBLES INFLAMMATOIRES TELS QUE L'ASTHME ET LA BRONCHO-PNEUMOPATHIE CHRONIQUE OBSTRUCTIVE (BPCO).
MA27935A 2002-05-08 2004-11-05 Derives hydroxy-tetrahydro-naphtalenyluree MA30728B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0210512.0A GB0210512D0 (en) 2002-05-08 2002-05-08 Tetrahydro-napthalene derivatives
GBGB0227262.3A GB0227262D0 (en) 2002-05-08 2002-11-21 Tetrahydro-naphthalene derivatives

Publications (1)

Publication Number Publication Date
MA30728B1 true MA30728B1 (fr) 2009-10-01

Family

ID=9936269

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27935A MA30728B1 (fr) 2002-05-08 2004-11-05 Derives hydroxy-tetrahydro-naphtalenyluree

Country Status (13)

Country Link
KR (1) KR101000688B1 (fr)
AR (1) AR039983A1 (fr)
CU (1) CU23422B7 (fr)
DO (1) DOP2003000642A (fr)
EC (1) ECSP045413A (fr)
GB (2) GB0210512D0 (fr)
GT (1) GT200300102A (fr)
MA (1) MA30728B1 (fr)
MY (1) MY155011A (fr)
PE (1) PE20040363A1 (fr)
PT (1) PT1506167E (fr)
UA (1) UA77301C2 (fr)
ZA (1) ZA200408993B (fr)

Also Published As

Publication number Publication date
PT1506167E (pt) 2007-12-10
KR101000688B1 (ko) 2010-12-10
GB0227262D0 (en) 2002-12-31
KR20040108784A (ko) 2004-12-24
CU23422B7 (es) 2009-09-08
ECSP045413A (es) 2005-01-03
DOP2003000642A (es) 2003-11-15
PE20040363A1 (es) 2004-07-03
GT200300102A (es) 2004-03-17
MY155011A (en) 2015-08-28
GB0210512D0 (en) 2002-06-19
UA77301C2 (en) 2006-11-15
AR039983A1 (es) 2005-03-09
ZA200408993B (en) 2006-01-25

Similar Documents

Publication Publication Date Title
TNSN05298A1 (fr) Derives de pyrazolo-quinazoline, procede pour leur preparation et leur utilisation comme inhibiteurs de kinases
JP7146809B2 (ja) 医薬組成物の調製におけるシトクロムｂｃ１複合体阻害剤の使用
NO20035473D0 (no) Oralt administrerte doseringsformer av GABA-analogprodrugs som har reduserttoksisitet
TNSN07349A1 (fr) Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur
TNSN04246A1 (fr) Derives d&#39;heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
WO2007110627A3 (fr) Sels de 3,7-diamino-10h-phénothiazine et utilisation correspondante
NO20033711D0 (no) Heteropolysykliske forbindelser og deres anvendelse som metabotrope glutamatatreseptorantagonister
EA200601802A1 (ru) Производные морфолина
MX2008016525A (es) Inhibidores heterocíclicos fusionados de d-amino ácido oxidasa.
MA27491A1 (fr) Derives de phenyl-ou heteroarylamino-alcanes comme antagonistes ou recepteur ip
WO2003027068A3 (fr) Amines substituees pour le traitement de la maladie d&#39;alzheimer
CY1107264T1 (el) Αποτελεσματα καταστολης ανοσοποιησης των παραγωγων pteridine
DK1569896T3 (da) Tetrahydronaphthalenderivater
LU91281I2 (fr) Preotact-hormone parathyroïde
MA29566B1 (fr) Composes chimiques
IL165004A0 (en) Hydroxy tetrahydro-naphthalenylurea derivatives
MA28429B1 (fr) Dérivés de 1H-thiéno [2,3-c] pyrazole utiles comme inhibiteurs de kinases
DK1572632T3 (da) Tetrahydro-naphthalenderivater som vanilloidreceptorantagonister
MXPA02011921A (es) Inhibidores de dipeptidasa acida n-acetilada-alfa-enlazada para el tratamiento de trastornos retinianos y glaucona.
WO2003066022A3 (fr) Preparation pharmaceutique stable pour le traitement des troubles gastro-intestinaux
ZA202204251B (en) Compounds and compositions for the treatment of parasitic diseases
MXPA05014143A (es) Derivados de cumarina para el tratamiento de trastornos oftalmicos.
MX2024014168A (es) Antagonistas de at2r y usos de estos
BR0214293A (pt) Composto e métodos para tratar um paciente que tenha, ou de prevenir um paciente de adquirir, uma doença ou condição e para produzir um composto ou um sal ou éster farmaceuticamente aceitável do mesmo
TW200640464A (en) Pharmaceutical composition comprising phenoxazinium compounds as an active ingredient